High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa

Molecular Therapy

Volumn 23, Issue 8, 2015, Pages 1368-1379

  Kühl, Tobias ^a   Mezger, Markus ^b   Hausser, Ingrid ^c   Handgretinger, Rupert ^b   Bruckner Tuderman, Leena ^a   Nyström, Alexander ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; ANTIINFLAMMATORY AGENT; COL7A1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL INFILTRATION; CELL THERAPY; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DERMAL HEALING; DERMOEPIDERMAL JUNCTION; DOSE RESPONSE; EPIDERMAL HEALING; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FIBER; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INTRADERMAL CELL DELIVERY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PROTEIN DEPOSITION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SKIN FIBROBLAST; SKIN INTEGRITY; WOUND HEALING; ANIMAL; CHEMISTRY; CYTOLOGY; DISEASE MODEL; EPIDERMIS; FIBROBLAST; IMMUNOLOGY; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; REGENERATION; SKIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; EPIDERMIS; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FIBROBLASTS; HUMANS; INFLAMMATION; INJECTIONS, INTRADERMAL; MESENCHYMAL STROMAL CELLS; MICE; REGENERATION; SKIN; WOUND HEALING;

EID: 84938421986     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.58     Document Type: Article

References (54)

1. Aymé, S, Rodwell, C, eds. (2013). 2013 Report on the State of the Art of Rare Disease Activities in Europe. Publisher: European Union, Brussels.
2. Griggs, RC, Batshaw, M, Dunkle, M, Gopal-Srivastava, R, Kaye, E, Krischer, J et al.; Rare Diseases Clinical Research Network. (2009). Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 96: 20-26.
3. Fine, JD, Bruckner-Tuderman, L, Eady, RA, Bauer, EA, Bauer, JW, Has, C et al. (2014). Inherited epidermolysis bullosa: updated recommendations on diagnosis and classifcation. J Am Acad Dermatol 70: 1103-1126.
4. Has, C and Bruckner-Tuderman, L (2014). The genetics of skin fragility. Annu Rev Genomics Hum Genet 15: 245-268.
5. Van Agtmael, T and Bruckner-Tuderman, L (2010). Basement membranes and human disease. Cell Tissue Res 339: 167-188.
6. Aumailley, M, Has, C, Tunggal, L and Bruckner-Tuderman, L (2006). Molecular basis of inherited skin-blistering disorders, and therapeutic implications. Expert Rev Mol Med 8: 1-21.
7. Chung, HJ and Uitto, J (2010). Type VII collagen: the anchoring fbril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin 28: 93-105.
8. Wertheim-Tysarowska, K, Sobczyiiska-Tomaszewska, A, Kowalewski, C, Skroriski, M, Swickowski, G, Kutkowska-Kazmierczak, A et al. (2012). The COL7A1 mutation database. Hum Mutat 33: 327-331.
9. van den Akker, PC, Jonkman, MF, Rengaw, T, Bruckner-Tuderman, L, Has, C, Bauer, JW et al. (2011). The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat 32: 1100-1107.
10. Uitto, J and Richard, G (2004). Progress in epidermolysis bullosa: genetic classifcation and clinical implications. Am J Med Genet C Semin Med Genet 131C: 61-74.
11. Fine, JD (2010). Inherited epidermolysis bullosa. Orphanet J Rare Dis 5: 12.
12. Bruckner-Tuderman, L, McGrath, JA, Robinson, EC and Uitto, J (2013). Progress in Epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Invest Dermatol 133: 2121-2126.
13. Bruckner-Tuderman, L (2014). Small-molecule therapies for genetic skin fragility. Mol Ther 22: 1724-1725.
14. Cogan, J, Weinstein, J, Wang, X, Hou, Y, Martin, S, South, AP et al. (2014). Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther 22: 1741-1752.
15. Venugopal, SS, Yan, W, Frew, JW, Cohn, HI, Rhodes, LM, Tran, K et al. (2013). A phase II randomized vehicle-controlled trial of intradermal allogeneic fbroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 69: 898-908.e7.
16. Petrof, G, Martinez-Queipo, M, Mellerio, JE, Kemp, P and McGrath, JA (2013). Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol 169: 1025-1033.
17. Wagner, JE, Ishida-Yamamoto, A, McGrath, JA, Hordinsky, M, Keene, DR, Woodley, DT et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363: 629-639.
18. Hünefeld, C, Mezger, M, Kern, JS, Nyström, A, Bruckner-Tuderman, L, Müller, I et al. (2013). One goal, different strategies-molecular and cellular approaches for the treatment of inherited skin fragility disorders. Exp Dermatol 22: 162-167.
19. Conget, P, Rodriguez, F, Kramer, S, Allers, C, Simon, V, Palisson, F et al. (2010). Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12: 429-431.
20. Bernardo, ME and Fibbe, WE (2013). Mesenchymal stromal cells: sensors and switchers of infammation. Cell Stem Cell 13: 392-402.
21. Németh, K, Leelahavanichkul, A, Yuen, PS, Mayer, B, Parmelee, A, Doi, K et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
22. Wu, Y, Chen, L, Scott, PG and Tredget, EE (2007). Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648-2659.
23. Sasaki, M, Abe, R, Fujita, Y, Ando, S, Inokuma, D and Shimizu, H (2008). Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 180: 2581-2587.
24. Lee, RH, Pulin, AA, Seo, MJ, Kota, DJ, Ylostalo, J, Larson, BL et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-infammatory protein TSG-6. Cell Stem Cell 5: 54-63.
25. Fritsch, A, Loeckermann, S, Kern, JS, Braun, A, Bösl, MR, Bley, TA et al. (2008). A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fbroblast therapy. J Clin Invest 118: 1669-1679.
26. Kern, JS, Loeckermann, S, Fritsch, A, Hausser, I, Roth, W, Magin, TM et al. (2009). Mechanisms of fbroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther 17: 1605-1615.
27. Haniffa, MA, Collin, M P, Buckley, CD and Dazzi, F (2009). Mesenchymal stem cells: the fbroblasts' new clothes? Haematologica 94: 258-263.
28. Nyström, A, Velati, D, Mittapalli, VR, Fritsch, A, Kern, JS and Bruckner-Tuderman, L (2013). Collagen VII plays a dual role in wound healing. J Clin Invest 123: 3498-3509.
29. Qi, Y, Jiang, D, Sindrilaru, A, Stegemann, A, Schatz, S, Treiber, N et al. (2014). TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fbrosis in murine full-thickness skin wounds. J Invest Dermatol 134: 526-537.
30. Uemura, R, Xu, M, Ahmad, N and Ashraf, M (2006). Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98: 1414-1421.
31. Maxson, S, Lopez, EA, Yoo, D, Danilkovitch-Miagkova, A and Leroux, MA (2012). Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med 1: 142-149.
32. Ennis, WJ, Sui, A and Bartholomew, A (2013). Stem Cells and Healing: Impact on Infammation. Adv Wound Care (New Rochelle) 2: 369-378.
33. Regauer, S, Seiler, GR, Barrandon, Y, Easley, KW and Compton, CC (1990). Epithelial origin of cutaneous anchoring fbrils. J Cell Biol 111(5 Pt 1): 2109-2115.
34. Tidman, MJ and Eady, RA (1985). Evaluation of anchoring fbrils and other components of the dermal-epidermal junction in dystrophic epidermolysis bullosa by a quantitative ultrastructural technique. J Invest Dermatol 84: 374-377.
35. Wong, T, Gammon, L, Liu, L, Mellerio, JE, Dopping-Hepenstal, PJ, Pacy, J et al. (2008). Potential of fbroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179-2189.
36. Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586.
37. Woodley, DT, Remington, J, Huang, Y, Hou, Y, Li, W, Keene, DR et al. (2007). Intravenously injected human fbroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15: 628-635.
38. Pacini, S (2014). Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Front Cell Dev Biol 2: 50.
39. Wenzel, D, Bayerl, J, Nyström, A, Bruckner-Tuderman, L, Meixner, A and Penninger, JM (2014). Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa. Sci Transl Med 6: 264ra165.
40. Prockop, DJ, Prockop, SE and Bertoncello, I (2014). Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. Stem Cells 32: 3055-3061.
41. Kaipe, H, Carlson, LM, Erkers, T, Nava, S, Molldén, P, Gustafsson, B et al. (2015). Immunogenicity of Decidual Stromal Cells in an Epidermolysis Bullosa Patient and in Allogeneic Hematopoietic Stem Cell Transplantation Patients. Stem Cells Dev (epub ahead of print).
42. Wong, VW, Rustad, KC, Akaishi, S, Sorkin, M, Glotzbach, JP, Januszyk, M et al. (2012). Focal adhesion kinase links mechanical force to skin fbrosis via infammatory signaling. Nat Med 18: 148-152.
43. Kern, JS, Grüninger, G, Imsak, R, Müller, ML, Schumann, H, Kiritsi, D et al. (2009). Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol 161: 1089-1097.
44. Boyd, AS and Roffwarg, D (2013). Cutaneous verrucous xanthoma in a bone marrow transplant recipient with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol 30: 480-483.
45. Tolar, J, Ishida-Yamamoto, A, Riddle, M, McElmurry, RT, Osborn, M, Xia, L et al. (2009). Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113: 1167-1174.
46. Perdoni, C, McGrath, JA and Tolar, J (2014). Preconditioning of mesenchymal stem cells for improved transplantation effcacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther 5: 121.
47. Bruckner-Tuderman, L, Nilssen, O, Zimmermann, DR, Dours-Zimmermann, MT, Kalinke, DU, Gedde-Dahl, T Jr et al. (1995). Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. J Cell Biol 131: 551-559.
48. Müller, I, Kordowich, S, Holzwarth, C, Isensee, G, Lang, P, Neunhoeffer, F et al. (2008). Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 40: 25-32.
49. Müller, I, Kordowich, S, Holzwarth, C, Spano, C, Isensee, G, Staiber, A et al. (2006). Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8: 437-444.
50. Cosset, FL, Takeuchi, Y, Battini, JL, Weiss, RA and Collins, MK (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69: 7430-7436.
51. Marx, JC, Allay, JA, Persons, DA, Nooner, SA, Hargrove, PW, Kelly, PF et al. (1999). High-effciency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fuorescent protein in human marrow stromal cells. Hum Gene Ther 10: 1163-1173.
52. Gieseke, F, Böhringer, J, Bussolari, R, Dominici, M, Handgretinger, R and Müller, I (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116: 3770-3779.
53. Nyström, A, Buttgereit, J, Bader, M, Shmidt, T, Ozcelik, C, Hausser, I et al. (2013). Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect. PLoS One 8: e64243.
54. Tanaka, T, Takahashi, K, Furukawa, F and Imamura, S (1994). The epitope for anti-type VII collagen monoclonal antibody (LH7:2) locates at the central region of the N-terminal non-collagenous domain of type VII collagen. Br J Dermatol 131: 472-476.